Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial

R. Sundar, N.B. Kumarakulasinghe, Y.H. Chan, K. Yoshida, T. Yoshikawa, Y. Miyagi, Y. Rino, M. Masuda, J. Guan, J. Sakamoto, S. Tanaka, A.L.K. Tan*, M.M. Hoppe, A.D. Jeyasekharan, C.C.Y. Ng, M. De Simone, H.I. Grabsch, J. Lee, T. Oshima*, A. Tsuburaya*P. Tan*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Web of Science)
Original languageEnglish
Number of pages10
JournalGut
DOIs
Publication statusE-pub ahead of print - 11 May 2021

Keywords

  • gastric cancer
  • chemotherapy
  • adjuvant treatment
  • COMPREHENSIVE MOLECULAR CHARACTERIZATION
  • CISPLATIN
  • CHEMOTHERAPY
  • 5-FLUOROURACIL
  • SENSITIVITY
  • DOCETAXEL
  • THERAPY
  • FAMILY
  • TUMORS
  • UFT

Cite this